StockNow
Calendar
Log in
U.S. Markets

Amgen (AMGN) announced positive results from the Phase 3 OASIZ-301 study of dazodalibep

ORIGINAL · NewsquawkAmgen (AMGN) announced positive results from the Phase 3 OASIZ-301 study of dazodalibepRead originalHide original

Both dazodalibep dosing regimens met the primary endpoint at Week 48, demonstrating statistically significant reductions in systemic disease activity compared with placebo, as measured by the ESSDAI score.

StockNow breaking-news AI analysis

Amgen announced positive OASIZ-301 results; a November 4 report gave ESSDAI improvements and said a second Phase III Sjögren's study was expected later in 2026.

News detail

Both dazodalibep dosing regimens met the primary endpoint at Week 48, demonstrating statistically significant reductions in systemic disease activity compared with placebo, as measured by the ESSDAI score.

1 stocks
AMGNAmgen Inc$462.78Current price

What do investors think?

Curious what other investors think?Log in to see reactions and join the conversation.
Log in to view reactions

StockNow uses AI to translate and analyze information and does not guarantee its accuracy or completeness.

Today's market highlights

A selection of stories drawing attention in the market.

See more
Geopolitics

Russia to update on the Abu Dhabi talks within the next hour, sources suggest

Geopolitics

Iran's Rezaei says that any new US attack would be met with the targeting of "distant" US military bases as well, Al Mayadeen reports; will not remove any enriched nuclear material from Iran

Geopolitics

Ukraine negotiator Umerov, after the Abu Dhabi talks, says talks should be multilateral, not trilateral; Europeans should be involved. Have good momentum to come to a solution before end-2026